Global private equity and venture capital news and research

AVG Ventures, Remeditex help cancer treatment company Bellicum to $34.4m Series B

8 Jan 2014

AVG Ventures and Remeditex Ventures have increased their backing of Bellicum Pharmaceuticals to help it raise $34.4m for its Series B round.

Sorry, to get access to this you need to subscribe for free.

In order to view more content, sign-up to our free daily newsletter.

If you would like to read the premium stories, have complete access to our breaking news and Limited Partner magazine you need to become a Premium Subscriber.

Subscribe to AltAssets today

Login to AltAssets

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016